Best Clinical Genomics Companies in San Diego, United States

Developer of non-invasive cancer detection methods. It offers a 5-hydroxymethylcytosine-based epigenomic platform and cell-free DNA-based assays to measure biological changes in cells and detect cancers with high mortality rates when they respond best to treatment.

Funding rounds

• May 2025Series C$21.8M
• May 2021Series C$70M

Founders & team

Dave MullarkeyChief Executive Officer

Investors

Pathology Asia Holdings

Developer of technologies for genome sequence and structure. Arima Genomics is developing a novel method of DNA sequencing that enables genome-scale phasing or haplotyping of DNA variants using a combination of proximity ligation (Hi-C), short-read DNA sequencing, and a proprietary probabilistic algorithm for haplotype assembly. The company calls its new method, HaploSeq, and is derived from work done by Selvaraj et al (Nature Biotechnology, 2013, Vol 31, pp-1111). The method addresses a currently unmet need for cost-effective and reliable methods for the phasing of variants. Arima has multiple SIBR grants from the Department of Health and human services to develop their method.

Provider of technology for RNA analysis to improve human health. The company offers new technologies in RNA biology to develop new medical treatments and diagnostic assays.

Funding rounds

• Mar 2025Grant (prize money)$1.7M
• Jun 2024Series A$7.5M
• May 2023Grant (prize money)$1.4M
• Jul 2022Grant (prize money)$259.6K

Founders & team

Byron PurseCo-Founder

Investors

Genoa Ventures, FusionX Ventures, Vertical Venture Partners, HHS

Tech stack

Cart FunctionalityCloudflareCloudflare Bot ManagementCookieyesCore-JsFormidable Form

Developer of gene therapies for treating cancer and liver orphan disease by using gene-editing technologies. It is developing CAR-T and gene therapy products for cancer and orphan diseases. Poseida uses its genome engineering capabilities for effectively silencing target genes or inserting therapeutic genes. Proprietary tools include piggyBac DNA Modification System, CRISPR, TALEN, and Footprint-Free Gene Editing System, which are clean (synthetic and virus-free) and can be surgically precise.

Provider of non-invasive tests for the detection of circulating tumor cells. The proprietary platform uses specialized assays and advanced digital pathology algorithms to identify circulating tumor cells from whole blood. The flagship product is Epic AR-V7 which detects the presence of AR-V7 biomarker in whole blood and associates it with the response rate for treatment with Zytiga and Xtandi. The first proposed application is metastatic castration-resistant prostate cancer.

Innovative medicines company reimagining medicine to improve and extend people’s lives. Focused on addressing society’s greatest disease burdens, it develops transformative, high-value treatments across various therapeutic areas, including cardiovascular, renal, metabolic, immunology, neuroscience, and oncology. The company embraces breakthrough science and new technologies to fight disease and improve patient outcomes. Committed to environmental, social, and governance (ESG) principles, it strives to make a positive impact on the world by providing access to innovative medicines, protecting the environment, and upholding high ethical standards. The company fosters a culture of inclusion, promoting diversity and belonging among its people. It also supports global health initiatives, including pandemic preparedness and disease elimination programs. The company engages in research and development, collaborations, and partnerships to discover and deliver innovative solutions for patients worldwide.

Developer of Antibody-drug conjugates to treat cancers, metabolic disorders, and cardiovascular disorders. The company has developed Engineered Precision Biologics (EPBs) by using proprietary genetic code technology to produce antibody-drug conjugates (ADCs) and immuno-oncology conjugates (IOCs) for treating cancers. The product pipeline includes ARX788 an anti-HER2 ADC currently being studied in breast cancer, gastric cancer, and other solid tumors, ARX517 for prostate cancer, and more. They have developed immuno-oncology conjugates for NASH, heart failure, and prostate cancer

Funding rounds

• Nov 2020Series E$200M
• Aug 2016Series E$45M
• Mar 2009Series D$10M
• Jul 2006Series C$55M

Founders & team

Lawson MacartneyPresident & Ceo

Investors

CMEA Capital, Tavistock Group, 5AM Ventures, Versant Ventures, Aravis, Maverick Ventures

Tech stack

WordpressBugherdMysqlPhpGsapUnderscore.Js

Provider of non-invasive prenatal genomic testing. The company's diagnostic platform is based on genomics, epigenomics, proteomics, and metabolomics. The company's products include a Preparent carrier test for prenatal genetic disorders, an Innatal prenatal screen for chromosomal-related disorders, hereditary cancer risk prediction, and Resura prenatal test for detecting monogenic disorders. The company also developing precision medicine for prenatal, perinatal, oncology, and gastroenterology diseases.

Funding rounds

• May 2021Post IPO$40M
• Feb 2021Post IPO—
• Dec 2020Post IPO$75M
• Apr 2020Series B$10M

Founders & team

Harry StylliCEO and Chairman of the Board

Investors

Athyrium Capital Management, Savitr Capital, TRITON FUNDS

Tech stack

WordpressMysqlPhpWistiaYoast SeoNginx

DTx Pharma is a provider of RNA-based therapeutics for personalized treatment across a wide range of therapeutic areas. The company has developed a proprietary technology based on lipidation allowing direct conjugation of long-chain fatty acids to siRNA, which enables delivery of siRNA therapeutics across multiple cell types.

AltheaDx, Inc. provides molecular diagnostics and PCR-based services. It offers molecular biomarker discovery, assay development, assay validation, and prospective/retrospective clinical trial testing services. The company also provides gene expression and genotyping analysis for pre-clinical and clinical applications. In addition, it offers discovery services, such as microarray analysis, real-time PCR, next-gen sequencing, quantitative PCR, mutation scanning, data analysis, race assay, and therapeutic siRNA; and diagnostic development services. Further, the company provides clinical trial services, such as enhanced clinical trial, predictive drug response, patient stratification and monitoring.

Developer of therapeutics to treat cancer. The company leverages a CRISPR-enabled platform to understand cancer to develop the next generation of targeted cancer therapies.

Funding rounds

• Apr 2023Series A$28M

Founders & team

Christian SchmedtCo-Founder

Investors

Andreessen Horowitz, Casdin Capital, Alexandria, S32, Section 32

Biological Dynamics has developed a proprietary lab-on-chip (LOC) platform (ACE) for direct and selective isolation of nanoparticles from physiological solutions. Its platform uses a direct-to-analyte approach for nanoparticles isolation (no isolation or sample prep). The company is developing minimally invasive diagnostic assays that detect cell-free dsDNA, exosomes, and other cellular debris.